Skip to main content

Table 1 Characteristics of patients with latent tuberculosis infection

From: House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study

Characteristic

Home follow-upa(N=986)

Clinic follow-upb(N=2932)

p-valuec

N

(%)

N

(%)

Female

549

(55.7)

1467

(50.0)

0.002

Median age

22

 

24

 

<0.001

(1st and 3rd quartile)

(10–31)

 

(13–35)

  

Age categories:

 

<0.001

 

< 6 years old

141

(14.3)

140

(4.8)

 

6 to < 18

277

(28.1)

967

(33.0)

18 to < 35

399

(40.5)

1085

(37.0)

35 and older

169

(17.1)

740

(25.2)

Place of birth:

 

0.008

 

Latin America

592

(60.0)

1573

(53.7)

 

Asia

243

(24.7)

837

(28.6)

USA

75

(7.6)

268

(9.1)

Africa

22

(2.2)

48

(1.6)

Europe

20

(2.0)

82

(2.8)

Unknown

34

(3.5)

124

(4.2)

 

Needed translation serviced

60

(6.1)

176

(6.0)

0.93

Patient referral reason:

 
 

TST converters and TB case contactse

220

(22.3)

229

(7.8)

<0.001

Correction and rehabilitationf

9

(0.9)

226

(7.7)

 

Postpartum womeng

59

(6.0)

169

(5.8)

TST+h from screening

698

(70.8)

2308

(78.7)

Prescribed 9Hi regimen

555

(56.3)

1595

(54.4)

0.30

  1. aPatients assigned home-based follow-up with a community health worker and public health nurse.
  2. bPatients with clinic-based follow-up.
  3. cSignificance testing with chi-square test or Wilcoxon rank-sum test.
  4. dPatients who spoke languages other than Spanish, Tagalog, Vietnamese, Cantonese, or Mandarin, and required use of a phone translation service or a family member for communication.
  5. eRecent tuberculin skin test converters and household contacts to active tuberculosis cases.
  6. fPatients from correctional and drug and alcohol rehabilitation facilities.
  7. gWomen treated more than 2 months after delivery of child.
  8. hTST+: Tuberculin skin test positive from routine screening.
  9. i Nine months of isoniazid as opposed to six months of isoniazid.